Alzheimer’s disease

Phase 2 · Completed

Registry enrollment: 260 participants

Study ages: 55 Years to 85 Years

No results-posting date in this record

Phase 2 / Phase 3 · Ongoing, no longer enrolling

Registry enrollment: 247 participants

Study ages: 50 Years and older

No results-posting date in this record

Phase 2 · Ongoing, no longer enrolling

Registry enrollment: 97 participants

Study ages: 50 Years to 85 Years

No results-posting date in this record

Phase 3 · Enrolling participants

Planned enrollment: 426 participants

Study ages: 55 Years to 90 Years

Recruiting sites listed in: Argentina, Brazil, Bulgaria, Canada, China and 10 more countries/territories (see details)

No results-posting date in this record

Phase 3 · Ongoing, no longer enrolling

Registry enrollment: 1,535 participants

Study ages: 55 Years to 90 Years

No results-posting date in this record

A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease

Phase 3 · Enrolling participants

Planned enrollment: 1,600 participants

Study ages: 55 Years to 80 Years

Recruiting sites listed in: Argentina, Australia, Canada, China, Taiwan and 2 more countries/territories (see details)

No results-posting date in this record